Роль приверженности пациентов в лечении гиперфосфатемии при хронической болезни почек


DOI: https://dx.doi.org/10.18565/nephrology.2020.2.84-95

А.М. Есаян, А.Р. Ринд

ФПО ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. И.П. Павлова» МЗ РФ, Санкт-Петербург, Россия
Цель исследования: рассмотреть вопросы приверженности к коррекции гиперфосфатемии у пациентов с хронической болезнью почек.
Развитие гиперфосфатемии – частое явление среди пациентов с хронической болезнью почек, в основном на терминальной стадии. Гиперфосфатемия сопряжена с более высокими показателями заболеваемости и смертности.
Приверженность пациентов к лечению гиперфосфатемии играет неотъемлемую роль в успешности коррекции данного состояния. В данном обзоре подробно рассмотрено пять групп факторов, оказывающих влияние на приверженность и включающие особенности пациента; болезни; методы проводимого лечения, его фармакоэкономические особенности; эффективность взаимодействия лечащего врача и пациента.
Ключевые слова: фосфат-связывающие препараты (ФСП), минерально-костные нарушения, гиперфосфатемия, приверженность к терапии, диетотерапия, диализ, хроническая болезнь почек
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Settineri S., Frisone F., Merlo E.M., et al. Compliance, adherence, concordance, empowerment, and self-management: five words to manifest a relational maladjustment in diabetes. Journal of Multidisciplinary Healthcare. 2019;12:299-314.

  2. World Health Organization (2003): Adherence to long-term therapies, evidence for action. Geneva: https://www.who.int/chp/knowledge/publications/adherence_report/en/

  3. Anghel L.A., Farcas A.M., Oprean RN. An overview of the common methods used to measure treatment adherence. Medicine and Pharmacy Reports. 2019;92(2):117–122.

  4. Вольская Е.А. Пациентский комплаенс. Обзор тенденций в исследованиях. Ремедиум. 2013;7:6–14.

  5. Messa P., Cerutti R., Brezzi B., Alfieri C., Cozzolino M.: Calcium and phosphate control by dialysis treatments. Blood. Purif. 2009;27:360–368.

  6. Gallieni M., De Luca N., Santoro D., Meneghel G., Formica M., Grandaliano G., Pizzarelli F., Cossu M., Segoloni G., Quintaliani G., Di Giulio S., Pisani A., Malaguti M., Marseglia C., Oldrizzi L., Pacilio M., Conte G., Dal Canton A., Minutolo R. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J. Nephrol. 2016;29:71–78.

  7. Ketteler M., Block G.A., Evenepoel P., Fukagawa M., Herzog C.A., McCann L., Moe S.M., Shroff R., Tonelli M.A., Toussaint N.D., Vervloet M.G., Leonard M.B. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann. Int. Med. 2018;168:422–430.

  8. KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int. 2017; 7(1):S1–S59.

  9. Tentori F., Wang M., Bieber B.A., Karaboyas A., Li Y., Jacobson S.H., Andreucci V.E., Fukagawa M., Frimat L., Mendelssohn D.C., Port F.K., Pisoni R.L., Robinson B.M. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. CJASN 2015;10:98–109.

  10. Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A., Pellegrini F., Saglimbene V., Logroscino G., Fishbane S., Strippoli G.F. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84:179–191.

  11. Bolasco P.G., Ghezzi P.M., Ferrara R., Maxia M., Pinna M., Logias F., Cogoni G., Cadinu F., Ghisu T., Contu B., Casu D., Passaghe M., Pilloni A., Ganadu M., Gazzanelli L. Effect of on-line hemodiafiltration with endogenous reinfusion (HFR) on the calcium-phosphorus metabolism: medium-term effects. Int. J. Artif. Organs. 2006;29:1042–1052.

  12. Messa P., Gropuzzo M., Cleva M., Boscutti G., Mioni G., Cruciatti A., Mazzolini S., Malisan M.R. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial. Transplant. 1998;13(6):43–48.

  13. Eloot S., Van Biesen W., Dhondt A., Van de Wynkele H., Glorieux G., Verdonck P., Vanholder R. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int. 2008;73:765–770.

  14. Ayus J.C., Mizani M.R., Achinger S.G., Thadhani R., Go A.S., Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J. Am. Soc. Nephrol. 2005;16: 2778–2788.

  15. Daugirdas J.T., Chertow G.M., Larive B., Pierratos A., Greene T., Ayus J.C., Kendrick C.A., James S.H., Miller B.W., Schulman G., Salusky I.B., Kliger A.S. Frequent Hemodialysis Network (FHN) Trial Group: Effects of frequent hemodialysis on measures of CKD mineral and bone disorders. J. Am. Soc. Nephrol. 2012;23:727–738.

  16. Lornoy W., De Meester J., Becaus I., Billiouw J.M., Van Malderen P.A., Van Pottelberge M. Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J. Renal. Nutr. 2006;16:47–53.

  17. Davenport A., Gardner C., Delaney M. Pan Thames Renal Audit Group: The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. Thepan thames renal audit. Nephrol. Dial. Transplant. 2010;25:897–901.

  18. Pedrini L.A., De Cristofaro V., Comelli M., Casino F.G., Prencipe M., Baroni A., Campolo G., Manzoni C., Colì L., Rggiero P., Acquistapace I., Auriemma L. Long-term effects of high-efficiency on-line haemodiafiltration on uraemic toxicity. A multicentre prospective randomized study. Nephrol. Dial. Transplant. 2011;26:2617–2624.

  19. Penne E.L., van der Weerd N.C., van den Dorpel M.A., Grooteman M.P., Levesque R., Nube M.J., Bots M.L., Blankestijn P.J., ter Wee P.M. CONTRAST Investigators: Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled convective transport study (CONTRAST). Am. J. Kidney Dis. 2010;55:77–87.

  20. Cupisti A., Gallieni M., Rizzo M.A., Caria S., Meola M., Bolasco P. Phosphate control in dialysis. Int J. Nephrol. Renovasc. Dis. 2013;6:193–205.

  21. Robinson B.M., Akizawa T., Jager K.J., Kerr P.G., Saran R., Pisoni R.L. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294–306.

  22. Kugler C., Maeding I., Russell C.L. Non-adherence in patients on chronic hemodialysis: an international comparison study. J Nephrol. 2011;24(3):366–375.

  23. Martins M.T., Silva L.F., Kraychete A., et al. Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis. BMC Nephrol. 2013;14:208

  24. Bleyer A.J., Hylander B., Sudo H., et al. An international study of patient compliance with hemodialysis. JAMA. 1999;281(13):1211–1213.

  25. Leggat J.E. Jr. Adherence with dialysis: a focus on mortality risk. Semin. Dial. 2005;18(2):137–141.

  26. Obialo C.I., Hunt W.C., Bashir K., Zager P.G. Relationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network. Clin. Kidney J. 2012;5(4):315–319.

  27. Al Salmi I., Larkina M., Wang M., Subramanian L., Morgenstern H., Jacobson S., Hakim R., Tentori F., Saran R., Akiba T., Tomilina N.A., Port F., Robinson B., and Pisoni R. Missed Hemodialysis Treatments: International Variation, Predictors, and Outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). AJKD. 2018;72(5):635–43

  28. Obialo C.I., Hunt W.C., Bashir K., Zager P.G. Relationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network. Clin Kidney J. 2012;5(4):315–319

  29. Brar A., Babakhani A.,Salifu M.O., Jindal R.M. Evaluation of non-adherence in patients undergoing dialysis and kidney transplantation: United States transplantation practice patterns survey. Transplant. Proc. 2014;46:1340–1346

  30. Chan K.E., Thadhani R.I., Maddux F.W. Adherence barriers to chronic dialysis in the United States. J. Am. Soc. Nephrol. 2014;25(11):2642–2648

  31. Kalantar-Zadeh K., Gutekunst L., Mehrotra R., Kovesdy C.P., Bross R., Shinaberger C.S., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010;5:519–30

  32. Cupisti A., Kalantar-Zadeh K. Management of natural and added dietary phosphorus burden in kidney disease. Semin. Nephrol. 2013;33(2):180–90.

  33. Karp H., Ekholm P., Kemi V., Itkonen S., Hirvonen T., Närkki S, et al. Differences among total and in vitro digestible phosphorus content of plant foods and beverages. J. Ren. Nutr. 2012;22(4):416–22.

  34. Jones W.L. Demineralization of a wide variety of foods for the renal patient. J. Ren. Nutr. 2001;11:90–6.

  35. Jones W.L. Demineralization of a wide variety of foods for the renal patient. J. Ren. Nutr. 2001;11:90–6.

  36. Benini O, D’Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a renal and insidious danger for renal patients. J. Ren. Nutr. 2011;21:303–8.

  37. Leon JB, Sullivan CM, Sehgal AR: The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Renal. Nutr. 2013;23:265–270.

  38. Bump M. Organic phosphorus versus inorganic phosphorus: empowering adult kidney patients with nutrition education. J. Renal. Nutr. 2016;26:31–3.

  39. León J.B., Sullivan C.M., Sehgal A.R. The prevalence of phosphorus-containing food additives in top-selling foods in grocery stores. J. Ren. Nutr. 2013;23(4):265–70.

  40. Sullivan C., Sayre S.S., Leon J.B., Machekano R., Love T.E., Porter D., et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA. 2009;301(6):629–35.

  41. Shutto Y., Shimada M., Kitajima M., Yamabe H., Saitoh Y., Saitoh H, et al. Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate. PLoS One. 2013;8(11).

  42. Caldeira D., Amaral T., David C., Sampaio C. Educational strategies to reduce serum phosphorus in hyperphosphatemic patients with chronic kidney disease: systematic review with meta-analysis. J. Ren. Nutr. 2011;21(4):285–94.

  43. Kalantar-Zadeh K. Patient education for phosphorus management in chronic kidney disease. Patient Prefer Adherence. 2013;7:379–90.

  44. Serfaty M.A., Haworth D., Blandhard M., Buszewicz M., Murad S., King M. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled study. Arch. Gen. Psychiatry. 2009;66(12):1332–1340.

  45. Fournet R.M. Technology and applications: how can they help dietitians? Ren. Nutr. Forum. 2014;33:1–6.

  46. Kahan S., Manson J.E. Nutrition counseling in clinical practice: how clinicians can do better. JAMA. 2017;318:1101–1102.

  47. D’Alessandro C., Piccoli G., Cupisti A. The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients BMC Nephrology. 2015,16:9 http://www.biomedcentral.com/1471-2369/16/9

  48. Fernández-Martín J.L., Carrero JJ, Benedik M, Bos WJ, Covic A, et. al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol. Dial. Transplant. 2013;28:1922–1935.

  49. Karamanidou C., Clatworthy J., Weinman J., Horne R. A systematic review of the prevalence anddeterminants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 9:2. Doi: 10.1186/1471-2369-9-2 PMID: 18237373

  50. Fissell R.B., Karaboyas A., Bieber B.A., et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial. Int. 2016;20(1):38–49.

  51. Erasmus R.T., Savory J., Wills M.R, Herman MM: Aluminum neurotoxicity in experimental animals. Ther. Drug. Monit. 1993;15:588–592.

  52. Spasovski G.B., Sikole A., Gelev S., Masin-Spasovska J., Freemont T., Webster I, Gill M, Jones C, De Broe ME, D’Haese PC. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol. Dial. Transplant. 2006;21:2217–2224.

  53. Malluche H.H., Mawad H., Monier-Faugere M.C. The importance of bone health in endstage renal disease: out of the frying pan, into the fire? Nephrol. Dial. Transplant. 2004;19(1):i9–i13.

  54. Apetrii M., Covic A., Massy Z.A. Magnesium supplementation: aconsideration in dialysis patients. Semin. Dial. 2018;31:11–14.

  55. Jamal S.A., Vandermeer B., Raggi P., et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268.

  56. Patel L., Bernard L.M., Elder G.J. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin. J. Am. Soc. Nephrol. 2016;11:232

  57. Floege J., Covic A.C., Ketteler M., et al. Long-term effects of the iron based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol. Dial. Transpl. 2017;32:1918–1926.

  58. Coyne D.W., Ficociello L.H., Parameswaran V., Anderson L., Vemula S., Ofsthun N.J., Mullon C., Maddux F.W., Kossmann R.J. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: a retrospective analysis of pharmacy data. Clin. Nephrol. 2017;88:59–67.

  59. Chiu Y.W., Teitelbaum I., Misra M., de Leon E.M., Adzize T., Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality o fife in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 2009;4:1089–1096.

  60. Daugirdas J.T., Blake P., Ing T. Bone disease. In: Wolters Kluwer Health. Philadelphia, PA Handbook of dialysis. 5th ed. Philadelphia, PA: Wolters Kluwer Health; 2015.

  61. Kalantar-Zadeh K., Parameswaran V., Ficociello L.H., et al. Real-world scenario improvements in serum phosphorus levels and pill burden in peritoneal dialysis patients treated with sucroferric oxyhydroxide. Am. J. Nephrol. 2018;47(3):153–161.

  62. Gray K., Ficociello L., Hunt A., Mullon C., Brunelli S. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide. International Journal of Nephrology and Renovascular Disease. 2019:121–8

  63. Monaco K., S. Writer Phosphate Binder Type Matters in Dialysis – Hospital admission rates, healthcare costs varied according to binder prescribed. MedPage Today March 28, 2020, National Kidney Foundation 2020. Spring Clinical Meetings.

  64. Coyne D., Ficociello L., Parameswaran V., Rosen M, Sprague S. et al. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Med. 2020;2(3):307–316.

  65. US DOPPS Practice Monitor. http://www.dopps.org/dpm/.Accessed April 17, 2020.

  66. Floege Ju.Phosphate binders in chronic kidney disease: a systematic review of recent data J. Nephrol. 2016;29:329–340.

  67. Угрехелидзе Д.Т., Ккуликов А.Ю. Фармакоэкономический анализ лекарственного средства Вельфоро® 500 (комплекс β-железа (iii) оксигидроксида, сахарозы и крахмала) в лечении гиперфосфатемии у пациентов с хронической болезнью почек. Фармакоэкономика: теория и практика. 2016;4(1):176–182.


Об авторах / Для корреспонденции

Есаян Ашот Мовсесович – д.м.н., профессор, заведующий кафедрой нефрологии и диализа ФПО ФГБОУ ВО «ПСПбГМУ им. акад. И.П. Павлова» МЗ РФ; Санкт-Петербург; Россия. Е-mail: essaian.ashot@gmail.com
Ринд Анастасия Рауфовна – аспирант кафедры нефрологии и диализа ФПО ФГБОУ ВО «ПСПбГМУ им. акад. И.П. Павлова» МЗ РФ; Санкт-Петербург, Россия. Е-mail: anastasiia.rind@gmail.com


Похожие статьи

К содержанию номера

Бионика Медиа